Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml;  ; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml   potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - doripenem 500mg ( as doripenem monohydrate) - powder for infusion - 500 mg - active: doripenem 500mg ( as doripenem monohydrate)

Evropská unie - angličtina - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibacterials for systemic use, - doribax is indicated for the treatment of the following infections in adults:nosocomial pneumonia (including ventilator-associated pneumonia);complicated intra-abdominal infections;complicated urinary tract infections.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - meropenem trihydrate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - meropenem trihydrate -

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension with strawberry flavour - 600mg/5ml+ 42.9mg/5ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml; potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml; potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

Kanada - angličtina - Health Canada

taro pharmaceuticals inc - clindamycin (clindamycin phosphate) - solution - 1% - clindamycin (clindamycin phosphate) 1% - antibiotics

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

2022 environmental science au pty ltd - imidacloprid; betacyfluthrin - suspension concentrate - imidacloprid guanidine active 50.0 g/l; betacyfluthrin pyrethroid active 25.0 g/l - insecticide - commercial area - general | industrial and/or domestic premises | public building/structure - external are | public building/str - ant | bed bug | cockroach | flea | spider | argentine ant | bedbug | ctenocephalides spp. | ground fleas | large cockroach | pharaoh ant | small cockroach